Vimarsana
Biggest News Aggregation in the World

Page 7 - Breakthrough Device Designations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Breakthrough Device Designations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Breakthrough Device Designations Today - Breaking & Trending Today

ONWARD® Launches Partnership with Service-Disabled - Vimarsana News

ONWARD® Launches Partnership with Service-Disabled

Agreement with Lovell provides rapid access to US Veterans Health Administration and US Department of Defense Military Health System...

ONWARD Schedules Webcast to Provide Half Year 2023 Business - Vimarsana News

ONWARD Schedules Webcast to Provide Half Year 2023 Business

Eindhoven, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to...

Natera Files Patent Infringement Suit Against NeoGenomics - Vimarsana News

Natera Files Patent Infringement Suit Against NeoGenomics

Natera, Inc. , a global leader in cell-free DNA testing, today announced that it has filed a lawsuit in the North Carolina Federal District Court against NeoGenomics Labs, Inc. for infringement of...

Natera Files Patent Infringement Suit Against NeoGenomics - Vimarsana News

Natera Files Patent Infringement Suit Against NeoGenomics

31.07.2023 - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has filed a lawsuit in the North Carolina Federal District Court against NeoGenomics Labs, Inc. ('NeoGenomics') for infringement of Natera's U.S. Patent ...

Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer - Vimarsana News

Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer

Study to evaluate clinical utility of ctDNA-guided treatment escalation for CRC patients; results expected to read out in mid-2024 ...